Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 116
- Registration Number
- NCT00772382
Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo of TA-7284
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 61
- Registration Number
- NCT00707954
- Locations
- 🇯🇵
P-One Clinic, Hachioji-city, Tokyo-to, Japan
Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: TA-650 3 mg/kgDrug: TA-650 6 mg/kgDrug: TA-650 10 mg/kg
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 327
- Registration Number
- NCT00691028
A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C
Phase 1
Completed
- Conditions
- Hepatitis C
- Interventions
- Drug: MP-424 (L), PEG-IFN-a-2b, RBVDrug: MP-424(H), PEG-IFN-a-2b, RBV
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT00630058
- Locations
- 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan
Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 324
- Registration Number
- NCT00628212
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- Drug: MP-424 (Telaprevir)
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 15
- Registration Number
- NCT00621296
- Locations
- 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
Phase 1
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: MP-424 (Telaprevir)
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT00591214
- Locations
- 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Phase 3
Completed
- Conditions
- Chronic Kidney DiseaseDialysisHyperphosphatemia
- Interventions
- Drug: Another Phosphate binder (Sevelamer)
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 632
- Registration Number
- NCT00542815
A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
Phase 3
Completed
- Conditions
- DialysisHyperphosphatemiaDyslipidemiaChronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 642
- Registration Number
- NCT00542386
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
Phase 2
Completed
- Conditions
- Coronary Artery DiseaseAngina, Unstable
- Interventions
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 140
- Registration Number
- NCT00508924
© Copyright 2025. All Rights Reserved by MedPath